POET Technologies (#POET) continues to build its position in the AI and data-center optical connectivity market, with Q2 2026 marking the company’s sixth consecutive quarter of sequential revenue growth. Q2 revenue reached $569,925, up 112% YoY and 13% QoQ, while the net loss narrowed to $11.3M ($0.07/share). The company ended the quarter with $796.3M in cash and short-term investments, providing substantial liquidity for commercialization and production expansion. 🔥 Key Commercial Catalysts 💰 Lumilens: POET has an initial $50M purchase order for its optical engines, with a broader agreement targeting more than $500M in cumulative revenue over five years. Importantly, the larger opportunity remains conditional on development, qualification and manufacturing scale-up milestones. ⚡ AI Optical Connectivity: POET’s Optical Interposer platform is designed to integrate optical and electronic components into compact, power-efficient optical engines aimed at AI/data-center applications. The company continues to target higher-speed optical products as AI networking requirements increase. 🏦 Institutional Interest: Q2 institutional data shows meaningful positioning changes in POET. Fintel reports a 39.88% increase in institutional long shares for the quarter, while Jane Street reported 9.51M shares, representing a 5.5% beneficial ownership stake as of June 30, 2026. 💎 ThinkSabio Signal Following the Q2 institutional data, #POET has qualified for both the TS Platinum and TS Diamond Reports, making it a stock worth monitoring for continued institutional-positioning changes. 🎯 What to Watch Commercial production → Lumilens qualification → additional production orders → optical-engine ramp → AI/data-center customer adoption → institutional positioning. Bottom Line: POET remains a high-growth, high-risk AI-photonics story. Revenue is still small relative to its long-term opportunity, but sequential revenue growth, significant liquidity, the Lumilens commercial commitment and increasing institutional positioning provide important milestones to watch. ⚠️ The $500M+ Lumilens figure is a target/framework, not guaranteed revenue. Commercial scale-up and customer qualification remain key execution risks. 📊 Want to track POET and other institutional moves? Explore ThinkSabio’s TS Platinum & TS Diamond Reports with a 7-day FREE trial. Start Your 7-Day FREE ThinkSabio Trial